AstraZeneca has entered into a multimillion-dollar agreement with San Francisco-based Algen Biotechnologies to advance gene-editing therapies in immunology, marking another major investment in artificial intelligence-powered drug discovery. The deal, announced on October 6, is valued at up to $555 million, consisting of upfront and milestone payments but no equity transaction.
The partnership gives AstraZeneca exclusive global rights to develop and commercialize therapies discovered using Algen’s proprietary AI platform, AlgenBrain™, which leverages CRISPR-based gene modulation to pinpoint and validate novel disease targets in human cells. Algen’s approach integrates large-scale genetic and cellular data with machine learning to identify links between gene expression and complex immune diseases, a domain where AstraZeneca plans to drive new treatment pipelines.
Algen, which originated from Nobel Laureate Jennifer Doudna's lab, will focus on early target discovery and preclinical work, while AstraZeneca will lead clinical development and commercialization. The deal illustrates the deepening collaboration between pharma giants and AI-driven biotech as the sector seeks to translate rapid genomic advances into next-generation therapies for chronic inflammatory and immune-based diseases.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!